<DOC>
	<DOCNO>NCT00069511</DOCNO>
	<brief_summary>This multi-center study . Neither study subject physician know treatment individual subject receiving . Subjects randomly assign ( like flip coin ) one five treatment group . The treatment group include four different dose group active study drug one group subject receive placebo . A 12 week follow period occur 12 week dose . The study endpoint reduction Hepatitis C viral load .</brief_summary>
	<brief_title>12 Week Study Anti-Viral Effect Oral UT-231B Non-cirrhotic Hepatitis C Patients Failed Interferon-based Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Patients must adults , positive Hepatitis C antibody test , genotype 1 , minimum 100,000 IU Hepatitis C virus nucleic acid testing , noncirrhotic Metavir score F03 ( equivalent ) liver biopsy , fail previous therapy Interferon Peg Interferon monotherapy , Interferon plus ribavirin , Peg Interferon ribavirin . Diabetics exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2004</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>